Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.51 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30282995 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL30098451 | 0.89 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5585999 | 0.89 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL30114633 | 0.88 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL15379126 | 0.85 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL4392645 | 0.84 | GPR119 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL30663949 | 0.84 | GPR119 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL30456375 | 0.84 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL5053496 | 0.80 | CHKA (0.44) | — | |
| SCHEMBL2297674 | 0.79 | NOTUM (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847181-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | AbbVie Inc. (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013170115-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | SIGNALRX PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188423-A1 | PI-3 KINASE INHIBITOR PRODRUGS | PI4KA, PI4KB, PI4K2B | CHRNB2 4268/4885CHRNA4 4164/4885CHRNA7 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.